Currently funded projects

Filter
Image: Graphic

Phase I clinical trial of intracranial injection of CAR-engineered NK cells in patients with recurrent HER2-positive glioblastoma

Institution: Georg-Speyer-Haus, Institut für Tumorbiologie und experimentelle Therapie, Frankfurt am Main
Applicant: Prof. Dr. Winfried Wels

Graphic

Leukocyte counts in capillary blood micro-samples based on targeted analysis of DNA methylation with digital droplet PCR - “Prick-Me”

Institution: Uniklinik RWTH Aachen Abteilung Stammzellbiologie und Cellular Engineering (AG Wagner)
Applicants: Dr. rer. nat. Mariangela Sociale
(Co-applicant: Prof. Dr. Dr. Wolfgang Wagner)

Image: magnetic resonance (MR)- positron emission tomography (PET

Anthropomorphes 4D Phantom

Institution: Arbeitsgruppe Electronic & Embedded Systems Development Lab Deutsches Krebsforschungszentrum (DKFZ)
Applicant: Steffen Seeber

Image: Graphic

A quality-managed software platform for quantitative microstructural tissue characterization using diffusivity imaging for early detection of cancer (Acronym: ARGOS-Imaging)

Institution: Universitätsklinikum Erlangen
Applicant: PD Dr. med. Sebastian Bickelhaupt
Co-applicant: PD Dr. med. Klaus Maier-Hein (Deutsches Krebsforschungszentrum Heidelberg)



Image: Graphic

The Role of Necroinflammation in Preclinical Kidney Xenotransplantation

Institution: Universitätsklinikum Carl Gustav Carus, Dresden
Applicant: Prof. Dr. med. Andreas Linkermann

BsAb directed to PSMA and CD3 recruit T cells against tumor cells (A). To avoid “off target” activation and thus side effects (B), expression of the selected target antigen should be restricted to tumor cells.

Drug substance production of the bispecific PSMAxCD3 antibody CC-1 to enable the conduct of a clinical study in patients with squamous cell carcinoma of the lung

Institution: Klinische Kooperationseinheit Translationale Immunologie, Deutsches Konsortium für Translationale Krebsforschung (DKTK), Deutsches Krebsforschungszentrum (DKFZ), Department für Innere Medizin, Universitätsklinikum Tübingen

The project involves the preparation and execution of a first-in-man study to investigate the potential of novel small molecule ferroptosis inhibitors for the prevention of ischemia/reperfusion injury upon liver transplantation.

Evaluation of ferroptosis inhibition for the treatment of ischemia/reperfusion injury upon liver transplantation: A first-in-man pilot study

Institution: Institut für Metabolismus und Zelltod, Helmholtz Zentrum München
Applicant: Dr. Marcus Conrad, Helmholtz Zentrum München

DKFZ-682 is a new inhibitor of the redox-buffer system regulated by thioredoxin. This system is particularly unstable in SCLC and thus enables the selectivity of the drug. The project promotes therapy optimization in a tumor model.

Preclinical optimization of a therapy concept based on novel gold-DTC complexes for lasting control of small cell lung cancer

Institution: Deutsches Krebsforschungzentrum (DKFZ)
Applicant: Nikolas Gunkel

LRIG2 will be inhibited by monoclonal antibodies what decreases lipid retention in adipocytes and reduces fat tissues. Investigations will be done in mice, pigs, and humans.

Obesity therapy and prevention by LRIG2 inhibition – a translational validation in a pig model

Institution: Institut für Molekulare Tierzucht und Biotechnologie, Ludwig-Maximilians-Universität München, Genzentrum
Applicant: PD Dr. Maik Dahlhoff, LMU München, Genzentrum